American Regent

American Regent is a well-established, commercial-stage pharmaceutical company with over 40 years of operation, primarily focused on the sterile injectables market. It maintains a diverse portfolio of generic and branded generic products, including key assets like Venofer (iron sucrose), Injectafer, and emergency medications such as epinephrine and glucagon. The company demonstrates vertical integration through manufacturing and a strategic focus on mitigating drug shortages, ensuring a reliable supply of essential medicines for hospitals and clinics. Recent expansion into animal health and strategic acquisitions indicate a focus on sustained growth.

Advanced pharmaceutical manufacturing and formulation for complex sterile injectables, including lyophilized products, solutions, and trace element combinations. Expertise in ensuring supply reliability and navigating FDA approval pathways for essential medicines.

American Regent competes with large generic injectable manufacturers like Hospira (Pfizer), Hikma, Fresenius Kabi, and Sandoz, as well as branded competitors in specific therapeutic areas (e.g., Pharmacosmos for iron products). Its key differentiator is a focused strategy on supply assurance and a portfolio targeting shortage-prone essential medicines.